Head to Head Comparison: Cellectar Biosciences (NASDAQ:CLRB) & Varex Imaging (NASDAQ:VREX)

Varex Imaging (NASDAQ:VREX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Varex Imaging and Cellectar Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Varex Imaging	1	1	2	1	2.60
Cellectar Biosciences	1	0	3	0	2.50

Varex Imaging presently has a consensus price target of $16.17, suggesting a potential upside of 52.37%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 291.46%. Given Cellectar Biosciences’ higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Varex Imaging.

Volatility & Risk

Varex Imaging has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Cellectar Biosciences has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Institutional and Insider Ownership

16.4% of Cellectar Biosciences shares are owned by institutional investors. 4.6% of Varex Imaging shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Varex Imaging and Cellectar Biosciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Varex Imaging	$844.60 million	0.53	-$70.30 million	($2.00)	-5.30
Cellectar Biosciences	N/A	N/A	-$21.79 million	($6.66)	-0.42

Cellectar Biosciences has lower revenue, but higher earnings than Varex Imaging. Varex Imaging is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Varex Imaging and Cellectar Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Varex Imaging	-9.64%	8.19%	3.63%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Varex Imaging beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.

About Varex Imaging

Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. The company operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. The company sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. It has operations in North America, South America, Europe, Russia, the Middle East, India, Africa, Asia, and Australia. Varex Imaging Corporation was incorporated in 2016 and is headquartered in Salt Lake City, Utah.

About Cellectar Biosciences

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.